Healthcare Industry Developments | BioTuesdays by Kilmer Lucas IR

Developments

Oculis treats first patient in trial of Privosegtor in ON

Oculis Holding (NASDAQ: OCS; XICE: OCS) has announced that the first patient has been treated in the PIONEER-1 registrational trial evaluating Privosegtor for the treatment of optic neuritis (ON). According to Oculis...

August 25, 2026

Developments

Activist hedge fund, Kaos Capital, calls for a Capricor Therapeutics strategic shift

Kaos Capital today issued a letter to its fellow Capricor Therapeutics (NASDAQ: CAPR) shareholders calling on them to support an immediate meeting with the Board of Directors regarding the Company’s future strategic...

August 21, 2026

Developments

Niagen expands Tru Niagen retail footprint

Niagen Bioscience (NASDAQ: NAGE) has announced that Tru Niagen, the company’s healthy-aging coenzyme nicotinamide adenine dinucleotide (NAD+)-boosting supplement, is now available at U.S. GNC and Sam’s Club retail...

August 20, 2026

Developments

Protagenic receives FDA pre-IND feedback for neuropeptide in GAD

Protagenic Therapeutics (OTCQB: PTIX) has announced that it has received written responses from the FDA to its Type B pre-Investigational New Drug (pre-IND) meeting request for PT00114, the company’s leading...

August 20, 2026

Developments

Revive to build biodefence and pandemic preparedness portfolio

Revive Therapeutics (OTCQB: RVVTF; CSE: RVV; Frankfurt: 31R) has outlined its strategy to build a focused biodefence and pandemic preparedness medical-countermeasure portfolio led by bucillamine, a thiol-based drug with...

August 19, 2026

Developments

Sunshine receives approval for generic Enalapril in Canadian market

Sunshine BioPharma (NASDAQ: SBFM) has announced Canadian regulatory approval of its generic ACE inhibitor, Enalapril, in oral tablets of 2.5mg, 5mg, 10mg and 20mg for the treatment of hypertension, heart failure, and...

August 19, 2026

Developments

Revelation selects Avance Clinical as CRO for TITAN study

Revelation Biosciences (NASDAQ: REVB) has announced that it has selected Avance Clinical, a full-service contract research organization (CRO) with global operations, to serve as the CRO for its Phase 2/3 adaptive-design...

August 19, 2026

Developments

FDA schedules Type A meeting for Ascelia’s Orviglance NDA

Ascelia Pharma (STO: ACE) has announced that the U.S. Food and Drug Administration (FDA) has scheduled a Type A meeting for September 9, 2026 to discuss the Complete Response Letter (CRL) issued on July 2, 2026...

August 17, 2026

Developments

OmniAb and Eli Lilly collaborate on new ion channel program

OmniAb (NASDAQ: OABI) has announced a global collaboration and license agreement with Eli Lilly and Company (NYSE: LLY) for a new ion channel program, leveraging OmniAb’s technology platform and expertise in ion channel...

August 17, 2026

Developments

Profound’s new real-time interventional MRI software to pave the way for full ‘TULSA days’

Profound Medical (NASDAQ: PROF; TSX: PRN) has announced the introduction of its latest Treatment Delivery Console (TDC) software being deployed across Profound’s TULSA-PRO-installed base. According to Profound, the TDC...

August 17, 2026

Developments

Profound launches ‘Let’s Huddle’, a global community supporting men through prostate care

Profound Medical (NASDAQ: PROF; TSX: PRN) has announced the launch of Let’s Huddle, a global patient community designed to empower men and their families with education, connection, and support throughout every...

August 14, 2026

Developments

Intermountain Health becomes first to bring Perimeter’s Claire to the operating room

Perimeter Medical Imaging AI (TSXV: PINK; OTCQX: PYNKF) has announced that Intermountain Health, in the Mountain West region, has become the first health system in the U.S. to commercially deploy Perimeter’s...

August 13, 2026

Developments

USPTO grants Alterity new composition of matter patent

Alterity Therapeutics (ASX: ATH; NASDAQ: ATHE) has announced that the United States Patent and Trademark Office (USPTO) has granted a new composition of matter patent for the company’s lead clinical asset, ATH434, an...

August 12, 2026

Developments

Valion announces U.S. government-funded Entolimod studies targeting lethal radiation-induced GI injury

Valion Bio (NASDAQ: VBIO) has announced that the Armed Forces Radiobiology Research Institute (AFRRI), under its contract with the National Institute of Allergy and Infectious Diseases, is conducting a U.S. Department...

August 12, 2026

Developments

Clearmind announces positive results for intranasal MEAI

Clearmind Medical (NASDAQ: CMND; FSE: CWY0) has announced positive permeation study results from its ongoing intranasal MEAI development program. According to Clearmind, early-stage studies of its intranasal MEAI...

August 11, 2026

Developments

SL Science co-authors Biomedicines article on γδ T Cell Therapy in Glioblastoma

SL Science Holding (NASDAQ: SLBT) has announced the publication of a peer-reviewed article in Biomedicines co-authored by SL Science leadership and clinical researchers from Taipei Medical University outlining a...

August 11, 2026

Developments

Vivos expands Greenway partnership

Vivos Therapeutics (NASDAQ: VVOS) has announced an expanded strategic engagement with closely held Greenway Health, a leading healthcare technology company, to deploy Greenway’s new AI-by-design Novare platform across...

August 11, 2026

Developments

Longeveron advances to final phase of XPRIZE Healthspan competition

Longeveron (NASDAQ: LGVN) announced that it has been selected from more than 600 worldwide applicants to advance to the final phase of the XPRISE Healthspan competition as a Milestone 2 Awardee team. The $1,000,000...

August 11, 2026

Developments

Silence reveals positive topline results from trial of divesiran in PV

Silence Therapeutics (NASDAQ: SLN) has announced positive topline results from the Phase 2 SANRECO trial of divesiran, a first-in-class siRNA, in 48 phlebotomy-dependent patients with polycythemia vera (PV). According...

August 10, 2026

Developments

USPTO grants Urteste patent for pancreatic cancer test

Urteste (WSE: URT) has announced that the United States Patent and Trademark Office (USPTO) granted a patent for Panuri, a non-invasive test for detecting pancreatic cancer. According to Urteste, the Panuri test is also...

August 6, 2026

Developments

Rise uplists to OTCQB; achieves DTC eligibility

Rise Nano Optics (CSE: EYE) (OTCQB: RNOLF) has announced that its common shares have been approved to commence trading on the OTCQB Venture Market and are also now DTC eligible, enhancing accessibility and efficiency of...

August 4, 2026

Developments

First site in Indiana offers Aclarion’s Nociscan for lower back pain

Aclarion (NASDAQ: ACON, ACONW) has announced that its Nociscan platform is now available at Goodman Campbell Brain & Spine at Ascension St. Vincent, marking the first site in Indiana to offer the technology...

August 4, 2026

Subscribe